Vigene Biosciences Revenue and Competitors

Claim your profile

Location

$10.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Vigene Biosciences's estimated annual revenue is currently $4.4M per year.(i)
  • Vigene Biosciences's estimated revenue per employee is $77,500
  • Vigene Biosciences's total funding is $10.5M.

Employee Data

  • Vigene Biosciences has 57 Employees.(i)
  • Vigene Biosciences grew their employee count by -49% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$41.1M2654%N/AN/A

Vigene Biosciences was founded in 2012 by senior scientists with expertise in the fields of virology and gene therapy. At Vigene, we strive to be the leading supplier of gene delivery technologies with the mission to advance biomedical research and to make gene therapy affordable. We offer both research-grade and cGMP-grade AAV, lentivirus, and adenovirus-based products and custom services. Some of our product offerings include ready-to-ship genome wide human cDNA ORFs on adenoviral or lentiviral vectors, AAV shRNA constructs, pre-made control GFP viruses, AAV biosensors developed in partnership with Janelia Research Campus, AAV alpha-synuclein vectors developed in partnership with The Michael J Fox Foundation, and many others. For more information, visit our websites for research (www.vigenebio.com) or cGMP (www.vigenegmp.com) services. You can also follow us on twitter at @VigeneBio.

keywords:N/A

$10.5M

Total Funding

57

Number of Employees

$4.4M

Revenue (est)

-49%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vigene Biosciences News

2022-04-13 - Global Lentiviral Vector Manufacturing Market Size GlobeNewswire

Global Lentiviral Vector Manufacturing Market Size GlobeNewswire

2022-04-06 - Global Viral Vector Manufacturing Market Trajectory & Analytics ... Business Wire

Global Viral Vector Manufacturing Market Trajectory & Analytics ... Business Wire

2019-09-08 - Going Viral: The Next Generation of AAV Vectors

... Gene Therapy (a unit of Catalent Biologics), the Chinese company WuXi Advanced Therapies, Novasep, Vigene Biosciences, and Virovek.

2019-09-07 - Vigene Biosciences Secures Institutional Investment in New ...

ROCKVILLE, Md., April 29, 2019 /PRNewswire/ -- Vigene Biosciences, Inc ("Vigene") a leading provider of viral vector products and services ...

2019-05-24 - Rockville biotech raising $7.5M for new manufacturing facility

This is the first raise for the business, which has been profitable and fueled growth organically up to this point.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M5719%N/A
#2
$7.4M574%N/A
#3
$7M574%N/A
#4
$9.6M58-3%N/A
#5
$7.6M580%N/A